Core Insights - The article highlights a significant breakthrough in clinical brain-machine interface technology, specifically for precise tumor boundary localization during surgery, marking the first global clinical trial of its kind [1][2]. Group 1: Technology Development - The clinical trial was conducted by the Aerospace Information Research Institute and the First Affiliated Hospital of Harbin Medical University, utilizing the NeuroDepth microelectrode developed by the Aerospace Institute [1]. - The technology includes a high-throughput neural signal detection device (AIRCAS-128) that synchronously collects and analyzes vast amounts of neural signals, converting raw signals into precise "lesion navigation" data for real-time tumor boundary assessment [1]. Group 2: Clinical Application - This technology overcomes the limitations of traditional neural electrodes, which could only detect signals from the brain's surface and shallow layers, allowing for detection across all brain regions, including deep brain areas [2]. - It can also simultaneously detect chemical signals such as dopamine and glutamate, providing comprehensive data to differentiate between tumor and normal tissue, which is crucial for accurate surgical planning and execution [2].

Core Viewpoint - The successful completion of the clinical trial for a brain-machine interface (BMI) technology developed by the Chinese Academy of Sciences marks a significant breakthrough in the precise localization of brain tumor boundaries during surgery, showcasing the potential for improved surgical outcomes and patient quality of life [3][4][6]. Group 1: Clinical Trial and Technology - The clinical trial involved the use of an implanted microelectrode array for precise tumor boundary localization during surgery, representing the first application of BMI technology in this context globally [3][4]. - The technology includes the NeuroDepth microelectrode and the AIRCAS-128 device, which allows for high-resolution, real-time detection of neural signals, enabling accurate identification of tumor boundaries [6][7]. - The microelectrode can detect neural activity at a spatial resolution of 15 micrometers and can be used throughout the entire brain, overcoming limitations of traditional methods [6][7]. Group 2: Clinical Implications - The BMI technology provides real-time navigation for neurosurgery, potentially increasing the rate of successful tumor removals while preserving healthy brain tissue [4][5]. - The clinical trial demonstrated successful tumor removal in a patient with glioma, leading to improved postoperative outcomes without new neurological deficits [7]. - The technology addresses the need for dynamic intraoperative identification of tumor boundaries, which has been a challenge in neurosurgery [7][8]. Group 3: Future Applications and Development - The Chinese Academy of Sciences plans to expand the application of BMI technology to areas such as sensory restoration for visually and hearing-impaired patients, as well as rehabilitation for stroke and hydrocephalus patients [9]. - The successful trial is seen as a critical step towards the clinical translation and industrialization of BMI technology, with ongoing collaboration expected to enhance technological advancements and clinical applications [8][9].

Core Insights - The clinical trial conducted by the Aerospace Information Innovation Research Institute and Harbin Medical University is the first in the world to apply brain-machine interface technology for precise boundary localization of deep brain tumors during surgery [1][2] - The trial utilized the NeuroDepth microelectrode and the AIRCAS-128 device, enabling real-time detection and analysis of neural signals, which aids in accurate tumor boundary identification [1][2] Group 1 - The clinical trial represents a significant breakthrough in domestically developed implantable clinical brain-machine interface technology [1] - The NeuroDepth microelectrode can detect signals from various brain regions, including deep brain areas, overcoming the limitations of traditional electrodes [1] - The technology allows for simultaneous detection of chemical signals, providing comprehensive data to differentiate between tumor and normal tissue [1] Group 2 - The trial was conducted on a glioma patient who experienced frequent seizures due to tumor pressure, and it successfully identified tumor boundaries while preserving functional areas [2] - The success of this clinical trial marks a critical step towards the clinical translation and industrialization of brain-machine interface technology [2]

Core Viewpoint - The successful clinical trial of a brain-machine interface for precise tumor boundary localization during surgery marks a significant breakthrough in China's independently developed clinical brain-machine interface technology [1][2]. Group 1: Technology and Innovation - The clinical trial utilized the NeuroDepth microelectrode developed by the Aerospace Information Innovation Research Institute, which allows for real-time detection of tumor boundary signals [1]. - The AIRCAS-128 device enables high-throughput synchronous detection and analysis of massive neural signals, transforming raw signals into precise "lesion navigation" data for real-time surgical guidance [1]. - This technology overcomes the limitations of traditional neural electrodes, which could only detect signals from the brain's surface and shallow layers, allowing for detection across all brain regions, including deep brain areas [1]. Group 2: Clinical Application - The trial was conducted on a glioma patient who experienced frequent seizures due to tumor pressure, successfully identifying tumor boundaries while protecting functional areas [2]. - The integration of imaging data with real-time feedback from NeuroDepth allowed for the complete removal of the tumor while minimizing damage to critical brain functions [2]. Group 3: Industry Implications - The success of this clinical trial is seen as a crucial step towards the clinical transformation and industrialization of brain-machine interface technology [2].